The US FDA has developed a “Long-Term National Strategy to Increase the Resiliency of the US Infant Formula Market” with action points and updated information for stakeholders. The report follows the 2023 Immediate National Strategy release, implemented in response to the 2022 infant formula recall and subsequent product shortages.
